| Nathan J Rudin, MD | |
|
5249 E Terrace Dr, Madison, WI 53718-8339 | |
| (608) 263-9550 | |
| (608) 263-0135 |
| Full Name | Nathan J Rudin |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 33 Years |
| Location | 5249 E Terrace Dr, Madison, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972567527 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 42596 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
Researchers at Northwestern University have discovered a key signaling mechanism that may promote the ability of highly aggressive malignant melanoma cells to metastasize, or spread from a primary tumor to distant sites within the body.
Scientists believe they may have found a preventative therapy for type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.
Vitamin A is an essential nutrient that the human body needs to function properly. But new research presented today at the American Physiological Society annual meeting at Experimental Biology 2017 in Chicago suggests that normal levels of vitamin A within a high-fat diet can negatively affect expression of liver genes associated with glucose and fat metabolism.
The 4th Annual Consumer Genetics Conference, taking place October 3-5 at the Seaport Hotel in Boston, will include a keynote presentation by George Church that will provide a forthright and candid assessment of new sequencing technologies, including the emergence of nanopore DNA sequencing, current trends in personal genomics, and projections on the future path of medical genomics.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 6 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
Researchers at Northwestern University have discovered a key signaling mechanism that may promote the ability of highly aggressive malignant melanoma cells to metastasize, or spread from a primary tumor to distant sites within the body.
Scientists believe they may have found a preventative therapy for type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.
Vitamin A is an essential nutrient that the human body needs to function properly. But new research presented today at the American Physiological Society annual meeting at Experimental Biology 2017 in Chicago suggests that normal levels of vitamin A within a high-fat diet can negatively affect expression of liver genes associated with glucose and fat metabolism.
The 4th Annual Consumer Genetics Conference, taking place October 3-5 at the Seaport Hotel in Boston, will include a keynote presentation by George Church that will provide a forthright and candid assessment of new sequencing technologies, including the emergence of nanopore DNA sequencing, current trends in personal genomics, and projections on the future path of medical genomics.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nathan J Rudin, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Nathan J Rudin, MD 5249 E Terrace Dr, Madison, WI 53718-8339 Ph: (608) 263-9550 |
News Archive
Researchers at Northwestern University have discovered a key signaling mechanism that may promote the ability of highly aggressive malignant melanoma cells to metastasize, or spread from a primary tumor to distant sites within the body.
Scientists believe they may have found a preventative therapy for type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.
Vitamin A is an essential nutrient that the human body needs to function properly. But new research presented today at the American Physiological Society annual meeting at Experimental Biology 2017 in Chicago suggests that normal levels of vitamin A within a high-fat diet can negatively affect expression of liver genes associated with glucose and fat metabolism.
The 4th Annual Consumer Genetics Conference, taking place October 3-5 at the Seaport Hotel in Boston, will include a keynote presentation by George Church that will provide a forthright and candid assessment of new sequencing technologies, including the emergence of nanopore DNA sequencing, current trends in personal genomics, and projections on the future path of medical genomics.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 6 days ago
Carlee Steinhaus, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2000 Observatory Dr, Madison, WI 53706 Phone: 608-262-3742 | |
Cynthia M Bender, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1821 S Stoughton Rd, Dean Medical Center, Madison, WI 53716 Phone: 608-260-6000 Fax: 608-260-6699 | |
Bradley John Rehrauer, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2500 Overlook Ter, Madison, WI 53705 Phone: 608-256-1901 | |
Courtney T. Hogendorn, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-8060 Fax: 608-263-5011 | |
Mr. Alexander Wilde, DPT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 752 N High Point Rd, Madison, WI 53717 Phone: 608-333-6534 | |
Deanna M Jewell, DO Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6420 | |
Nalini Sehgal, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5249 E Terrace Dr, Madison, WI 53718 Phone: 608-263-9550 Fax: 608-263-0135 |